Operating Lease, Right-of-Use Asset of Amylyx Pharmaceuticals, Inc. from 10 Jan 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Amylyx Pharmaceuticals, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 10 Jan 2022 to 30 Sep 2025.
  • Amylyx Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $5,476,000, a 7.4% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Amylyx Pharmaceuticals, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,476,000 +$376,000 +7.4% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $5,812,000 +$3,043,000 +110% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $1,256,000 -$1,996,000 -61% 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $1,771,000 -$1,954,000 -52% 31 Dec 2024 10-Q 06 Nov 2025 2025 Q3
Q3 2024 $5,100,000 +$911,000 +22% 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $2,769,000 -$1,874,000 -40% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $3,252,000 -$1,836,000 -36% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $3,725,000 -$1,799,000 -33% 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $4,189,000 -$1,762,000 -30% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $4,643,000 -$1,726,000 -27% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $5,088,000 -$1,697,000 -25% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $5,524,000 +$524,000 +10% 31 Dec 2022 10-K 22 Feb 2024 2023 FY
Q3 2022 $5,951,000 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $6,369,000 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $6,785,000 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $5,000,000 10 Jan 2022 10-K 22 Feb 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.